BRMU8602999U - medicamento "rosuvastatina + metformina" em forma combinada para doenças cardiovasculares - Google Patents

medicamento "rosuvastatina + metformina" em forma combinada para doenças cardiovasculares

Info

Publication number
BRMU8602999U
BRMU8602999U BRMU8602999-1U BRMU8602999U BRMU8602999U BR MU8602999 U BRMU8602999 U BR MU8602999U BR MU8602999 U BRMU8602999 U BR MU8602999U BR MU8602999 U BRMU8602999 U BR MU8602999U
Authority
BR
Brazil
Prior art keywords
insulin
rosuvastatin
cardiovascular diseases
metformine
hypertension
Prior art date
Application number
BRMU8602999-1U
Other languages
English (en)
Inventor
Walter Junior Santos
Original Assignee
Walter Junior Santos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter Junior Santos filed Critical Walter Junior Santos
Priority to BRMU8602999-1U priority Critical patent/BRMU8602999U/pt
Priority to PCT/BR2007/000349 priority patent/WO2008058358A2/en
Publication of BRMU8602999U publication Critical patent/BRMU8602999U/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

O MEDICAMENTO "ROSUVASTATINA + METFORMINA EM FORMA COMBINADA PARA DOENçAS CARDIOVASCULARES, resuma-se a combinação de dois medicamentos utilizados contra as doenças cardiovasculares são a principal causa de morte em nosso país. Há nítida correlação entre o ganho ponderal e o excesso de peso com risco de doenças cardiovasculares. O excesso de peso predispõe a estas doenças devido anormalidades no metabolismo dos lípides, glicose e pressão arterial. A resistência à insulina / hiperinsulinemia parece ser um fator de risco independente de outros fatores de risco associados, como a obesidade, hiperlipidemia e hipertensão, tanto em homens como em mulheres. A insulina e os fatores de crescimento semelhantes à insulina estimulam a atividade das células musculares lisas e estão envolvidas na aterogênese e mesmo na reestenose que se segue ao repara coronário pela angioplastia. Outros efeitos da insulina estão relacionados aos mecanismos que contribuem para o desenvolvimento tanto da hipertensão como da dislipidemia. O MEDICAMENTO "ROSUVASTATINA + METFORMINA" EM FORMA COMBINADA PARA DOENCAS CARDIOVASCULARES, diminuindo a resistência insulínica, a pressão arterial, o ganho ponderal e melhorando o perfil lipídico destes paciente, reduziriam muito a probabilidade de eventos cardiovasculares e conseqüentemente o óbito dessa natureza em nossa população.
BRMU8602999-1U 2006-11-16 2006-11-16 medicamento "rosuvastatina + metformina" em forma combinada para doenças cardiovasculares BRMU8602999U (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BRMU8602999-1U BRMU8602999U (pt) 2006-11-16 2006-11-16 medicamento "rosuvastatina + metformina" em forma combinada para doenças cardiovasculares
PCT/BR2007/000349 WO2008058358A2 (en) 2006-11-16 2007-11-14 Descriptive report of the patent of invention of the medicament 'rosuvastatin + metformin' in combined form for cardiovascular diseases.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRMU8602999-1U BRMU8602999U (pt) 2006-11-16 2006-11-16 medicamento "rosuvastatina + metformina" em forma combinada para doenças cardiovasculares

Publications (1)

Publication Number Publication Date
BRMU8602999U true BRMU8602999U (pt) 2008-07-08

Family

ID=39402026

Family Applications (1)

Application Number Title Priority Date Filing Date
BRMU8602999-1U BRMU8602999U (pt) 2006-11-16 2006-11-16 medicamento "rosuvastatina + metformina" em forma combinada para doenças cardiovasculares

Country Status (2)

Country Link
BR (1) BRMU8602999U (pt)
WO (1) WO2008058358A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2823397C (en) 2011-01-07 2020-03-10 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
MX2014008189A (es) 2012-01-06 2015-02-12 Elcelyx Therapeutics Inc Composiciones y metodos para tratar trastornos metabolicos.
ES2832773T3 (es) 2012-01-06 2021-06-11 Anji Pharma Us Llc Composiciones de biguanida y métodos de tratamiento de trastornos metabólicos
EP2872127A1 (en) * 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol

Also Published As

Publication number Publication date
WO2008058358A3 (en) 2009-04-16
WO2008058358A2 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
BRMU8602999U (pt) medicamento "rosuvastatina + metformina" em forma combinada para doenças cardiovasculares
Lei et al. Pharmacological properties of geraniol–a review
Huang et al. Repurposing psychiatric drugs as anti-cancer agents
Belcaro et al. Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients
Nisly et al. Canagliflozin, a new sodium–glucose cotransporter 2 inhibitor, in the treatment of diabetes
da Luz et al. Red wine and equivalent oral pharmacological doses of resveratrol delay vascular aging but do not extend life span in rats
Koyasu et al. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: a one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease
Kokkinaki et al. Chemically synthesized Secoisolariciresinol diglucoside (LGM2605) improves mitochondrial function in cardiac myocytes and alleviates septic cardiomyopathy
Hennekens et al. Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions
Bampi et al. Depression-like behavior, hyperglycemia, oxidative stress, and neuroinflammation presented in diabetic mice are reversed by the administration of 1-methyl-3-(phenylselanyl)-1H-indole
Vianna et al. In Vivo Anti‐Diabetic Activity of the Ethanolic Crude Extract of Sorbus decora CK Schneid.(Rosacea): A Medicinal Plant Used by Canadian James Bay Cree Nations to Treat Symptoms Related to Diabetes
Chen et al. The role of flavonoids in the prevention and management of cardiovascular complications: A narrative review
CO2021013251A2 (es) Derivados de insulina sensibles a la glucosa
PT1680112E (pt) N-(5-adamantano-1-il-metoxi-pentil)desoxinojirimicina ou um seu sal aceite na indústria farmacêutica para ser usado no tratamento da resistência à insulina
US20160346340A1 (en) Compositions including milk thistle and methods for the treatment of various disorders using the same
BRMU8602970U (pt) medicamento "telmisartam + metformina" em forma combinada para doenças cardiovasculares
Ewenighi et al. Responses to glycemic control therapy according to age, gender, level of adiposity, and duration of diabetes in type 2 diabetic patients.
BRMU8602979U (pt) medicamento "atorvastatina + metformina" em forma combinada para doenças cardiovasculares
BRMU8602991U (pt) medicamento "candesartana + metformina" em forma combinada para doenças cardiovasculares
Graham et al. Limitations of drug concentrations used in cell culture studies for understanding clinical responses of NSAIDs
Mounithaa et al. Effect of Piperine on an Nrf2/Keap 1 Signalling Mechanism in Adipose Tissue of High Fat Diet and Sucrose-Induced Experimental Diabetic Rats.
BRMU8602968U (pt) medicamento "ramipril + metformina" em forma combinada para doenças cardiovasculares
BRMU8403417U (pt) medicamento sinvastatina + metformina em forma combinada para doenças cardiovasculares
Nettelblad et al. Psoralens used for cosmetic sun tanning: an unusual cause of extensive burn injury
BRMU8403463U (pt) medicamento combinado amlodipino + metformina em forma combinada para doenças cardiovasculares

Legal Events

Date Code Title Description
B03A Publication of an application: publication of a patent application or of a certificate of addition of invention
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.